MHIF Celebrates Major Research Milestone for Patients

The Minneapolis Heart Institute Foundation (MHIF) is proud to celebrate a significant research milestone that reflects our continued commitment to advancing cardiovascular care. Our leadership in the LEADR clinical trial contributed directly to the recent regulatory approval of Medtronic’s newly approved OmniaSecure™ ICD lead.

Allina Health Minneapolis Heart Institute (AHMHI) was not only among the first sites to enroll patients in the OmniaSecure global clinical trial, but is also the first center in the Upper Midwest to offer this innovative technology commercially to patients. Congratulations to Drs. Kris Krueger, John Zakaib, Matt Olson, and R. Dent Underwood, along with the entire MHIF research team, for their outstanding work and dedication.

“This is an important new concept in transvenous defibrillator leads utilizing a robust and durable design but resulting in a very small lead diameter,” said John Zakaib, MD, cardiac electrophysiologist at AHMHI and researcher at MHIF. "It’s been a long road, but it’s been incredibly satisfying to participate in this process because this device is going to help a lot of people. We are confident this new innovation will result in better and safer outcomes for patients in the long term.”

The OmniaSecure lead represents a major advancement in implantable cardioverter‑defibrillator therapy. At 64% smaller than traditional defibrillation leads, it is designed to reduce anatomical disruption and enhance the long-term patient experience. This is a great example of how research advances care and options for patients.

Learn more about the OmniaSecure™ defibrillation lead from Allina Health’s announcement or discover more treatment options and the latest research for heart rhythm disorders here.